Test Code CMVGS Cytomegalovirus Antibody, IgG, Serum
Specimen Required
Supplies: Sarstedt Aliquot Tube 5 mL (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.6 mL
Collection Instructions: Centrifuge and aliquot serum into plastic vial
Useful For
Determining whether a patient has had previous exposure to or recent infection with cytomegalovirus, including pregnant women.
This test is not useful for screening blood or plasma donors, or neonatal screening.
Method Name
Electrochemiluminescence Immunoassay (ECLIA)
Reporting Name
CMV Ab, IgG, SSpecimen Type
SerumSpecimen Minimum Volume
0.6 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 28 days |
| Frozen | 180 days | |
| Ambient | 7 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
| Additives (eg, biocides, antioxidants) | Reject |
Clinical Information
Cytomegalovirus (CMV) is a member of the Herpesviridae family of viruses and usually causes asymptomatic infection after which it remains latent in patients, primarily within bone marrow-derived cells. Primary CMV infection in immunocompetent individuals may also manifest as a mononucleosis-type syndrome, similar to primary Epstein-Barr virus infection, with fever, malaise, and lymphadenopathy.
Cytomegalovirus is a significant cause of morbidity and mortality among bone marrow or solid organ transplant recipients, individuals with AIDS, and other immunosuppressed patients due to virus reactivation or a newly acquired infection. Infection in these patient populations can affect almost any organ and lead to multiorgan failure. CMV is also responsible for congenital disease among newborns and is one of the TORCH infections (toxoplasmosis, other infections including syphilis, rubella, CMV, and herpes simplex virus).
Cytomegalovirus seroprevalence increases with age. In the US, the prevalence of CMV specific antibodies increases from approximately 36% in children aged 6 to 11 years to over 91% in adults older than 80 yearsr.(4)
Reference Values
Negative
Reference values apply to all ages.
Interpretation
Negative
Negative for CMV IgG. False negative results may occur in immunocompromised patients.
Borderline
Recommend follow-up testing in 10-14 days if clinically indicated.
Positive
CMV IgG antibodies detected, which indicate recent or remote infection.
Cautions
Sera collected very early during the acute stage of infection may have undetectable levels of cytomegalovirus (CMV) IgG.
The CMV IgG assay should not be used alone to diagnose CMV infection. Results should be considered in conjunction with clinical presentation, patient history, and other laboratory findings. In cases of suspected disease, submit a second specimen for testing in 10 to 14 days.
The detection of CMV-specific IgG antibodies in a single sample indicates a previous exposure to CMV but is not sufficient to distinguish between an acute or latent infection.
The CMV IgM and IgG results should not be used alone to diagnose CMV infection. Results should be considered in conjunction with clinical presentation, patient history and other laboratory findings.
Performance characteristics have not been evaluated in immunosuppressed patients or organ transplant recipients and have not been established for cord blood or for testing of neonates. Immunocompromised patients may have impaired immune responses and nonreactive IgG results may be due to delayed seroconversion and, therefore, do not rule out current infection.
Immune complexes or other immunoglobulin aggregates present in patient specimens may cause increased nonspecific binding and produce false-positive results.
Potential cross-reactivity for CMV IgG with varicella-zoster virus IgG, measles IgG, mumps IgG and parvovirus B19 IgG and could not be ruled out. The potential cross-reactivity with E. coli and autoimmune markers could not be ruled out.
Samples should not be taken from patients receiving therapy with high biotin doses (ie, > 5 mg/day) until at least 8 hours following the last biotin administration.
Day(s) Performed
Monday through Saturday
Report Available
Same day/1 to 3 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
86644
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| CMVGS | CMV Ab, IgG, S | 22244-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| GCMV | CMV Ab, IgG, S | 22244-8 |